Overview
The investigators will study the Ileal interposition to the treatment of weight regain after Roux-en-Y gastric bypass, assessing weight loss, body composition, quality of life, metabolic biomarkers, inflammatory biomarkers, and incretin hormones
Description
This prospective, controlled, randomized intervention study will investigate the Ileal interposition to the treatment of weight regain after Roux-en-Y gastric bypass, assessing weight loss, body composition, health-related quality of life, metabolic biomarkers, inflammatory biomarkers, and incretin hormones. The participants will also be assessed for alcohol abuse, depressive symptoms, level of physical activity, eating disorder symptoms, and dumping syndrome.
Eligibility
Inclusion Criteria:
- Patients submitted to initial laparoscopic after initial Roux-en-Y gastric bypass for at least 3 years
- Loss of excess weight between 60 to 80%
- Rate of weight regain ≥60%
- Body mass index ≥ 40 kg/m2 or ≥ 35 kg/m2, with at least 2 comorbidities associated with obesity
- Present a previous evaluation by the multidisciplinary team with a favorable opinion of the revision surgery.
Exclusion Criteria:
- Active chemical dependency on alcohol and/or illicit drugs
- Severe psychotic or depressive disorder or history of suicide attempts in the last 12 months
- Eating behavior disorder (uncontrolled)
- Secondary causes of obesity
- Pregnancy
- Severe organ failure
- Active neoplastic
- Infectious or inflammatory disease
- Severe coagulopathy
- High anesthetic-surgical risk
- Intellectual inability
- Lack of preoperative follow-up